Kronos Bio Inc Stock

$0.88

0.00% day before yesterday

Nasdaq, Jun 26, 03:30 pm CET

ISIN

US50107A1043

Symbol

KRON

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Kronos Bio Inc Stock price

$0.88

-18.12 95.37% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.00 0.00%

ISIN

US50107A1043

Symbol

KRON

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$53.7m

Enterprise Value

$-46.1m

Net debt

$-99.7m

Cash

$99.7m

Shares outstanding

61.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

5.84 | -

EV/Sales

negative | -

EV/FCF

0.85

P/B

0.67

Financial Health

Equity Ratio

70.42%

Return on Equity

-98.29%

ROCE

-50.47%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$9.2m | $0.0

EBITDA

$-49.1m | $-92.8m

EBIT

$-50.6m

Net Income

$-64.5m | $-80.9m

Free Cash Flow

$-54.4m

Growth (TTM | estimate)

Revenue

21.08% | -100.00%

EBITDA

53.51% | -50.34%

EBIT

53.04%

Net Income

44.59% | 6.08%

Free Cash Flow

43.99%

Margin (TTM | estimate)

Gross

EBITDA

-534.56% | -

EBIT

-550.46%

Net

-701.53% | -

Free Cash Flow

-591.55%

EPS

$-1.07

FCF per Share

$-0.89

Short interest

1.66%

Employees

10.00

Rev per Employee

$990.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Kronos Bio Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Kronos Bio Inc forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Kronos Bio Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Kronos Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	9.19 9.19	21% 21% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	25 25	38% 38% 276%
- Research and Development Expense	34 34	54% 54% 374%
EBITDA	-49 -49	54% 54% -535%
- Depreciation and Amortization	1.46 1.46	28% 28% 16%
EBIT (Operating Income) EBIT	-51 -51	53% 53% -551%
Net Profit	-64 -64	45% 45% -702%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kronos Bio Inc Stock News

Neutral

Market Watch

●

8 days ago

Kronos Bio Completes Sale to Concentra Biosciences

Kronos Bio completed its sale to Concentra Biosciences for 57 cents a share in cash plus contingent value rights related to cost savings and potential proceeds from disposition of drug candidates.

Neutral

Business Wire

●

about 2 months ago

KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kronos Bio, Inc. (NasdaqGS: KRON) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Kronos will receive $0.57 in cash per share plus one non-tradeable cont...

Neutral

Business Wire

●

about 2 months ago

Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Kronos (Nasdaq: KRON) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shar...

More Kronos Bio Inc News

Company Profile

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, which engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic transcription factors, small cell, prostate cancer, and MYC-driven cancers. The company was founded by Angela Koehler and Joshua Kazam in 2017 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Deborah Knobelman
Employees	10
Founded	2017
Website	www.kronosbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now